Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients

Trial Profile

Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine without aura
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 24 Mar 2017 Planned End Date changed from 1 Feb 2017 to 9 May 2018.
    • 24 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 9 May 2018.
    • 11 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top